Flutemetamol (18F): A β-amyloid positron emission tomography tracer for alzheimer's and dementia diagnosis

Drugs of Today

Volumn 50, Issue 3, 2014, Pages 219-229

  De Lartigue, J ^a  

^a Jane de Lartigue Scientific Communications ^*  (United Kingdom)

Author keywords

Alzheimer's disease; Diagnostic; Flutemetamol (18F); Positron emission tomography; Radiopharmaceuticals

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; CEREBELLUM CORTEX; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIZZINESS; DOSIMETRY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG STRUCTURE; DYSPNEA; ELEVATED BLOOD PRESSURE; FLUSHING; HEADACHE; HUMAN; IMAGE ANALYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; THORAX PAIN; TREATMENT INDICATION;

ALZHEIMER'S DISEASE; DIAGNOSTIC; FLUTEMETAMOL (18F); POSITRON EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; ANIMALS; BENZOTHIAZOLES; BRAIN; CLINICAL TRIALS, PHASE III AS TOPIC; DEMENTIA; DRUG APPROVAL; HUMANS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84897448121     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.3.2116672     Document Type: Article

References (54)

1. alzheimer, a., Stelzmann, r.a., Schnitzlein, h.n., Murtagh, F.r. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin anat 1995, 8(6): 429-31
2. Blennow, K., de Leon, M.J., Zetterberg, h. Alzheimer's disease. Lancet 2006, 368(9533): 387-403 (Pubitemid 44108123)
3. robertson, E.D., Mucke, L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314(5800): 781-4 (Pubitemid 44706637)
4. Burns, a., Lliffe, S. Alzheimer's disease. BMJ 2009, 338: b158
5. Ferri, C.o., prince, M., Brayne, h. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366(9503): 2112-7 (Pubitemid 41797645)
6. alzheimer's Disease International. Policy Brief for Heads of Government: The Global Impact of Dementia 2013-2050. http://www.alz.co.uk/research/ globalimpactdementia2013.pdf. accessed January 10, 2014
7. hardy, J., Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580): 353-6 (Pubitemid 34790756)
8. Sperling, r.a., Lavoilette, p.S., o'Keefe, K. et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. neuron 2009, 63(2): 178-88
9. Jakob-roetrie, r., Jacobsen, h. Alzheimer's disease: from pathology to therapeutic approaches. angew Chem Int Ed Engl 2009, 48(17): 3030-59
10. Bacskai, B.J., hickey, g.a., Skoch, J. et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. proc natl acad Sci U S a 2003, 100(21): 12462-7 (Pubitemid 37271582)
11. Delacourte, a. [Diagnosis of Alzheimer's disease]. ann Biol Clin (paris) 1998, 56(2): 133-42
12. gay, B.E., Taylor, K.I., hohl, U., Tolnay, M., Staehelin, h.B. The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. J nutr health aging 2008, 12(2): 132-7 (Pubitemid 351219630)
13. Lopponen, M., raiha, I., Isoaho, r., Vahlberg, T., Kivela, S.L. Diagnosing cognitive impairment and dementia in primary health care - a more active approach is needed. age ageing 2003, 32(6): 606-12 (Pubitemid 37461568)
14. Mason, n.S., Mathis, C.a., Klunk, W.E. Positron emission tomography radioligands for in vivo imaging of A plaques. J Labelled Comp radiopharm 2013, 56(3-4): 89-95
15. Dishino, D.D., Welch, J., Kilbourn, M.r., raichle, M.E. Relationship between lipophilicity and brain extraction of C- 11-labelled radiopharmaceuticals. J nucl Med 1983, 24(11): 1030-8 (Pubitemid 14206457)
16. Waterhouse, r.n. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 5(6): 376-89 (Pubitemid 37489828)
17. Klunk, W.E., Engler, h., nordberg, a. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. ann neurol 2004, 55(3): 306-19 (Pubitemid 38269583)
18. Mathis, C., Wang, Y., holt, D.p., huang, g.F., Debnath, M., Klunk, W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003, 46(13): 2740-54 (Pubitemid 36702542)
19. rowe, C.C., ng, S., ackermann, U. et al. Imaging beta-amyloid burden in aging and dementia. neurology 2007, 68(20): 1718-25 (Pubitemid 46763260)
20. Ikonomovic, M., Klunk, W.E., abrahamson, E. et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131(pt. 6): 1630-45 (Pubitemid 351806448)
21. Koole, M., Lewis, D.M., Buckley, C. et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging. J nucl Med 2009, 50(5): 818-22
22. Mathis, C., Lopresti, B.J., Mason, n.S. et al. Comparison of the amyloid imaging agents (F-18) 3'-F-PIB and (C-11) PIB in Alzheimer's disease and control subjects. J nucl Med 2007, 48(Suppl. 2): 56p
23. nelissen, n., Van Laere, K., Thurfjell, L. et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J nucl Med 2009, 50(8): 1251-9
24. Vandenberghe, r., Thurfjell, L., owenius, r., Brooks, D., Koole, M., Bormans, g., nelissen, n. Phase I study of the 18F-labelled benzothiazole derivative (18F)AH110690 as an in vivo biomarker of ad-related brain amyloidosis. 1st Clin Trials alzheimer's Dis Conf (September 17-19, Montpellier, France) 2008, abst 015
25. Vandenberghe, r., Van Laere, K., Ivanoiu, a. et al. Phase II study of the 18F labelled PiB derivative GE067. 12th Int Conf alzheimer's Dis relat Disord (ICaD) (July 11-16, Vienna, austria) 2009, abst 01-4
26. Vandenberghe, r., Van Laere, K., Ivanoiu, a. et al. 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. ann neurol 2010, 68(3): 319-29
27. Wolk, D., grachev, I., Buckley, C. et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. arch neurol 2011, 68(11): 1398-403
28. Klunk, W.E., Mathis, C.a. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr opin neurol 2008, 21(6): 683-7
29. gE healthcare. Vizamyl, Flutemetamol F18 Injection, Prescribing Information. gE healthcare, october 2013. http://www3.gehealthcare.com/en/ products/Categories/~/media/Downloads/us/product/product-Categories/ nuclear-Imaging-agents-non-gatekeeper/Vizamyl/gEhealthcare-Vizamyl-prescribing- Information.pdf. accessed January 11, 2014
30. Snellman, a., rokka, J., Lopez-picon, F.r. et al. Pharmacokinetics of (18F)flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J nucl Med Mol Imaging 2012, 39(11): 1784-95
31. Snellman, a., Lopez-picon, F.r., rokka, J. et al. Small animal PET imaging of beta-amyloid deposition in the brain of APP23, Tg2576 and APPswe-PS1dE9 mice with (18F)flutemetamol. World Mol Imaging Congr (September 5-8, Dublin, Ireland) 2012, abst p058
32. Senda, M., Sasaki, M., Fujikawa, K., paterson, C., Mcparland, B. Biodistribution and radiation dosimetry of Flutemetamol (18F) injection in Japanese healthy volunteers. 59th annu Meet Soc nucl Med (SnM) (June 9-13, Miami) 2012, abst 1510
33. herholz, K., Ebmeier, K. Clinical amyloid imaging in Alzheimer's disease. Lancet neurol 2011, 10(7): 667-70
34. Mathis, C., Ikonomovic, M., Mason, n.S. et al. Pharmacologic and pharmacokinetic equivalence studies of GE-067 to PiB. 12th Int Conf alzheimer's Dis relat Disord (ICaD) (July 11-16, Vienna, austria) 2009, abst p2-007
35. Van Laere, K., Vandenberghe, r., Law, I. et al. Uptake of (18F)flutemetamol in healthy volunteer, Alzheimer's disease and mild cognative imparement subjects in a phase II clinical trial. Eur J nucl Med Mol Imaging 2009, 36(Suppl. 2): abst op145
36. Ikonomovic, M., price, J., abrahamson, E. et al. Postmortem correlations of flutemetamol and pittsburgh compound-B binding in eight (C-11)PIB imaged brains. 6th hum amyloid Imaging (haI) Conf (January 12-13, Miami) 2012, abst
37. Buckley, C., Farrar, g., Brooks, D., heurling, K. Intensity anchors for reading (18F)flutemetamol amyloid images. 6th hum amyloid Imaging (haI) Conf (January 12-13, Miami) 2012, abst 5
38. hatashita, S., Yamasaki, h., Suzuki, Y., Tanaka, K., Taniguchi, K., Wakebe, T., hayakawa, h. (18F)Flutemetamol amyloidbeta PET imaging compared with (11C) PIB across the spectrum of Alzheimer's disease. annu Meet Eur assoc nucl Med (EanM) (october 19-23, Lyon) 2013, abst p495
39. Thurfjell, L., Lundqvist, r., Koikkalainen, J. et al. Comparison of biomarkers from PET (18F)flutemetamol amyloid imaging and structural MRI. 13th Int Conf alzheimer's Dis relat Disord (ICaD) (July 10-15, honolulu) 2010, abst IC-p-140
40. Duara, r., Lowenstin, D., Shen, Q. et al. Comparison of [F- 18] flutemetamol PET imaging and MTA measures in Alzheimer disease. alzheimer's assoc Int Conf (aaIC) (July 16-21, paris) 2011, abst p4-051
41. De Weer, a.-S., Vandenblucke, M., nelissen, n., Farrar, g., Thurfjell, L., Van Laere, K., Vandenberghe, r. The flutemetamol in flanders' aging population (FLUFLAG) study: Prevalence of a positive scan in cognitively intact elderly individuals. 6th hum amyloid Imaging (haI) Conf (January 12- 13, Miami) 2012, abst 12
42. Duff, K., Foster, n., hoffman, J. Practice effects and amyloid deposition: A method for enriching samples in clinical trials. 7th hum amyloid Imaging (haI) Conf (January 16-18, Miami) 2013, abst 12
43. Duff, K., Foster, n., Dennett, K. et al. Amyloid deposition and cognition in older adults: The effects of premorbid intellect. 7th hum amyloid Imaging (haI) Conf (January 16-18, Miami) 2013, abst
44. Buckley, C., Ikonomovic, M., Smith, a. et al. Flutemetamol F 18 injection PET images reflect brain beta-amyloid levels. alzheimer's assoc Int Conf (aaIC) (July 14-19, Vancouver, Canada) 2012, abst o1-04-2
45. Salloway, S., gamez, J., Curtis, C. et al. (18F)Flutemetamol PET imaging: Predictive values, sensitivity and specificity of blinded visual interpretations. 11th Int Conf alzheimer parkinson Dis (aD/pD) (March 6-10, Florence, Italy) 2013, abst 178
46. Smith, a., Buckley, C., Sherwin, p. et al. Evaluation of the histopathology underlying (18F)flutemetamol PET imaging. 7th hum amyloid Imaging (haI) Conf (January 16-18, Miami) 2013, abst
47. Salloway, S., Curtis, C., gamez, J. Sensitivity and specificity of clinical diagnosis of Alzheimer's disease compared with (18F)flutemetamol PET image interpretation. 11th Int Conf alzheimer parkinson Dis (aD/pD) (March 6-10, Florence) 2013, abst
48. Sherwin, p., Wolber, J., Longenecker, F. Effectiveness of an electronic training program to teach interpretation of (18F)flutemetamol PET amyloid images. 7th hum amyloid Imaging (haI) Conf (January 16-18, Miami) 2013, abst 57
49. Walker, Z., Inglish, F., Sadowsky, C. et al. Reproducibility of [18F]flutemetamol pet amyloid image interpretation. 21st World Congr neurol (September 21-26, Vienna, austria) 2013, abst 2898
50. Wolk, D., Buckley, C., grachev, I., heurling, K., hamilton, r., arnold, S. [18F]-Flutemetamol amyloid PET imaging in patients with normal pressure hydrocephalus. alzheimer's assoc Int Conf (aaIC) (July 16-21, paris) 2011, abst p4-078
51. hamilton, r., patel, S., Lee, E.B. et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. ann neurol 2010, 68(4): 535-40
52. arnold, S., rinne, J., Wong, D. et al. Prospective and retrospective evaluation of (18F)flutemetamol for beta-amyloid detection in the brain of living subjects with normal pressure hydrocephalus. alzheimer's assoc Int Conf (aaIC) (July 14- 19, Vancouver) 2012, abst o1-04-5
53. Wong, D., Moghakar, a., rigamonti, D. et al. An in vivo evaluation of cerebral cortical amyloid with ((18)F)flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol 2013, 15(2): 230-7
54. Lundqvist, r., Lilja, J., Thomas, B.a., Loetjoenen, J., Villemagne, V.L., rowe, C.C., Thurfjell, L. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J nucl Med 2013, 54(8): 1472-8.